What is Centauri Therapeutics?
Centauri Therapeutics is a UK-based biotechnology firm specializing in immunotherapy. The company utilizes its proprietary Alphamer® platform to engineer the immune system, targeting drug-resistant infections and other diseases with high unmet medical needs. This innovative approach positions Centauri Therapeutics at the forefront of developing novel therapeutic strategies in a challenging and evolving healthcare landscape.
How much funding has Centauri Therapeutics raised?
Centauri Therapeutics has raised a total of $43.5M across 4 funding rounds:
Unspecified
$4.3M
Angel/Seed
$1.5M
Series A
$32.6M
Unspecified
$5.1M
Unspecified (2016): $4.3M, investors not publicly disclosed
Angel/Seed (2017): $1.5M, investors not publicly disclosed
Series A (2022): $32.6M supported by Boehringer Ingelheim Venture Fund, Evotec, and REPAIR Impact Fund
Unspecified (2025): $5.1M featuring Carb-X
Key Investors in Centauri Therapeutics
Carb-X
Carb-X is a global non-profit accelerator focused on combating dangerous drug-resistant bacteria by supporting the development of new antibiotics and other life-saving products. They invest in early-stage antibacterial innovation.
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science and first-in-class therapeutics across various modalities, aiming to redefine care standards and develop new medicines.
REPAIR Impact Fund
The REPAIR Impact Fund, backed by Novo Holdings, focuses on replenishing the anti-infective pipeline by investing in early-stage therapies to combat antimicrobial resistance.
What's next for Centauri Therapeutics?
With this major enterprise-level funding, Centauri Therapeutics is poised for significant expansion and acceleration of its research and development pipeline. The strategic investment will likely fuel the advancement of its Alphamer® platform, enabling the company to progress its lead candidates through clinical trials and towards commercialization. This backing signals strong confidence in Centauri's technology and its potential to revolutionize treatment paradigms for infectious diseases and beyond, marking a critical phase in its growth trajectory.
See full Centauri Therapeutics company page
